While allogeneic hematopoietic stem cell transplantation is currently the only available treatment for PNP deficiency, our data suggest that combined pharmacological blockade of dCK and TLR7 signaling could represent an alternative therapeutic strategy. This evidence concerns the gene DCK and purine nucleoside phosphorylase deficiency.